Terms: = Brain cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2
43 results:
1. Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel fgfr4 inhibitors for the treatment of colorectal cancer.
Fang B; Lai Y; Yan H; Ma Y; Ni Z; Zhu Q; Zhang J; Ye Y; Wang M; Wang P; Wang Y; Zhang S; Hui M; Wang D; Zhao Y; Li X; Wang K; Liu Z
Eur J Med Chem; 2023 Nov; 259():115703. PubMed ID: 37556948
[TBL] [Abstract] [Full Text] [Related]
2. Structural basis for FGF hormone signalling.
Chen L; Fu L; Sun J; Huang Z; Fang M; Zinkle A; Liu X; Lu J; Pan Z; Wang Y; Liang G; Li X; Chen G; Mohammadi M
Nature; 2023 Jun; 618(7966):862-870. PubMed ID: 37286607
[TBL] [Abstract] [Full Text] [Related]
3. Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness.
Gabler L; Jaunecker CN; Katz S; van Schoonhoven S; Englinger B; Pirker C; Mohr T; Vician P; Stojanovic M; Woitzuck V; Laemmerer A; Kirchhofer D; Mayr L; LaFranca M; Erhart F; Grissenberger S; Wenninger-Weinzierl A; Sturtzel C; Kiesel B; Lang A; Marian B; Grasl-Kraupp B; Distel M; Schüler J; Gojo J; Grusch M; Spiegl-Kreinecker S; Donoghue DJ; Lötsch D; Berger W
Acta Neuropathol Commun; 2022 Apr; 10(1):65. PubMed ID: 35484633
[TBL] [Abstract] [Full Text] [Related]
4. Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring fgfr4 activation.
Nam Y; Shin I; Kim Y; Ryu S; Kim N; Ju E; Sim T
Neoplasia; 2022 Jan; 24(1):34-49. PubMed ID: 34864570
[TBL] [Abstract] [Full Text] [Related]
5. Genomic comparison between cerebrospinal fluid and primary tumor revealed the genetic events associated with brain metastasis in lung adenocarcinoma.
Deng Z; Cui L; Li P; Ren N; Zhong Z; Tang Z; Wang L; Gong J; Cheng H; Guan Y; Yi X; Xia X; Zhou R; He Z
Cell Death Dis; 2021 Oct; 12(10):935. PubMed ID: 34642306
[TBL] [Abstract] [Full Text] [Related]
6. Fibroblast Growth Factor Receptor-4 Expression in Pituitary Adenomas is Associated with Aggressive Tumor Features.
Durcan E; Keskin FE; Ozkaya HM; Sirolu S; Sahin S; Korkmaz OP; Gazioglu N; Tanriover N; Comunoglu N; Oz B; Kizilkilic O; Kadioglu P
Exp Clin Endocrinol Diabetes; 2022 Feb; 130(2):125-133. PubMed ID: 34255320
[TBL] [Abstract] [Full Text] [Related]
7. Expression of GLUT3 and HIF-1
Mei T; Wang Z; Wu J; Liu X; Tao W; Wang S; Chen F
Biomed Res Int; 2020; 2020():1682352. PubMed ID: 32908869
[TBL] [Abstract] [Full Text] [Related]
8. fgfr4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.
Garcia-Recio S; Thennavan A; East MP; Parker JS; Cejalvo JM; Garay JP; Hollern DP; He X; Mott KR; Galván P; Fan C; Selitsky SR; Coffey AR; Marron D; Brasó-Maristany F; Burgués O; Albanell J; Rojo F; Lluch A; de Dueñas EM; Rosen JM; Johnson GL; Carey LA; Prat A; Perou CM
J Clin Invest; 2020 Sep; 130(9):4871-4887. PubMed ID: 32573490
[TBL] [Abstract] [Full Text] [Related]
9. Urinary protein biomarkers for pediatric medulloblastoma.
Hao X; Guo Z; Sun H; Liu X; Zhang Y; Zhang L; Sun W; Tian Y
J Proteomics; 2020 Aug; 225():103832. PubMed ID: 32474013
[TBL] [Abstract] [Full Text] [Related]
10. Age and pre quit-day attrition during smoking cessation treatment.
Conroy HE; Jacquart J; Baird SO; Rosenfield D; Davis ML; Powers MB; Frierson GM; Marcus BH; Otto MW; Zvolensky MJ; Smits JAJ
Cogn Behav Ther; 2020 Sep; 49(5):361-373. PubMed ID: 32343190
[TBL] [Abstract] [Full Text] [Related]
11. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel fgfr4 inhibitor fisogatinib (BLU-554).
Li W; Sparidans R; El-Lari M; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
Int J Pharm; 2020 Jan; 573():118842. PubMed ID: 31759109
[TBL] [Abstract] [Full Text] [Related]
12. Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study.
Lee JH; El-Damasy AK; Seo SH; Gadhe CG; Pae AN; Jeong N; Hong SS; Keum G
Bioorg Med Chem; 2018 Nov; 26(21):5596-5611. PubMed ID: 30385226
[TBL] [Abstract] [Full Text] [Related]
13. Epidemiology and biomarker profile of pituitary adenohypophysial tumors.
Mete O; Cintosun A; Pressman I; Asa SL
Mod Pathol; 2018 Jun; 31(6):900-909. PubMed ID: 29434339
[TBL] [Abstract] [Full Text] [Related]
14. fgfr4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors.
Ezzat S; Wang R; Pintilie M; Asa SL
Oncotarget; 2017 Jan; 8(2):3481-3494. PubMed ID: 27966451
[TBL] [Abstract] [Full Text] [Related]
15. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast cancer brain Metastases.
Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
[TBL] [Abstract] [Full Text] [Related]
16. Proximity Labeling Reveals Molecular Determinants of fgfr4 Endosomal Transport.
Haugsten EM; Sørensen V; Kunova Bosakova M; de Souza GA; Krejci P; Wiedlocha A; Wesche J
J Proteome Res; 2016 Oct; 15(10):3841-3855. PubMed ID: 27615514
[TBL] [Abstract] [Full Text] [Related]
17. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC
Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683
[TBL] [Abstract] [Full Text] [Related]
18. Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers.
Hernández-Ramírez LC; Gabrovska P; Dénes J; Stals K; Trivellin G; Tilley D; Ferrau F; Evanson J; Ellard S; Grossman AB; Roncaroli F; Gadelha MR; Korbonits M;
J Clin Endocrinol Metab; 2015 Sep; 100(9):E1242-54. PubMed ID: 26186299
[TBL] [Abstract] [Full Text] [Related]
19. Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics.
Balogun JA; Monsalves E; Juraschka K; Parvez K; Kucharczyk W; Mete O; Gentili F; Zadeh G
Endocr Pathol; 2015 Mar; 26(1):63-70. PubMed ID: 25403448
[TBL] [Abstract] [Full Text] [Related]
20. Endoscopic endonasal transsphenoidal approach to large and giant pituitary adenomas: institutional experience and predictors of extent of resection.
Juraschka K; Khan OH; Godoy BL; Monsalves E; Kilian A; Krischek B; Ghare A; Vescan A; Gentili F; Zadeh G
J Neurosurg; 2014 Jul; 121(1):75-83. PubMed ID: 24785323
[TBL] [Abstract] [Full Text] [Related]
[Next]
